A Therapeutic Alternative in the Management of Fibromyalgia

Introduction: Fibromyalgia is a condition that affects up to 5% of the population and causes significant deterioration of the quality of life for the sufferer, so it is a therapeutic challenge. The objective of the present study was to describe the experience of the AtlasPROfilax® method in patient...

Full description

Bibliographic Details
Main Authors: Jair Malagón, Mariana Villaveces, Lluis Manent
Format: Article
Language:English
Published: Fundación Universitaria Juan N. Corpas 2017-11-01
Series:Revista Cuarzo
Subjects:
Online Access:https://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/221
Description
Summary:Introduction: Fibromyalgia is a condition that affects up to 5% of the population and causes significant deterioration of the quality of life for the sufferer, so it is a therapeutic challenge. The objective of the present study was to describe the experience of the AtlasPROfilax® method in patients with fibromyalgia diagnosed according to the criteria of the American College of Reumatology (ACR) 2010. Methodology: A cross - sectional study with 63 patients with fibromyalgia was done. Patients were monitored two and six months after applying the AtlasPROfilax® method, in order to evaluate the pain level by visual analogue scale VAS and reevaluate ACR criteria in the follow-up appointment. Results: The average age of patients was 48.5 SD 12.6 years, 95.24% were female. 100% of patients improved pain (initial VAS of 8 vs 4 and 3 after two and six months respectively) and these were significant results. A reduction of widespread pain index as well as a reduction in the presence of symptoms such as fatigue, non-restorative sleep and cognitive disorders that are typical of fibromyalgia were also found in 46% of cases Conclusion: This study has provided evidence of the effectiveness of the neuromuscular stimulation method of the suboccipital musculature called AtlasPROfilax® in the treatment of fibromyalgia. Randomized and controlled studies are required to demonstrate the medium and long term effectiveness of this therapeutic alternative.
ISSN:0121-2133
2500-7181